Key clinical point: Subcutaneous sumatriptan significantly reduces cilostazol-induced headache in patients with migraine without aura compared with placebo.
Major finding: Sumatriptan injection significantly reduced headache score from 0 to 2 hours (P = .0003). The difference in median headache scores was significant at 2 hours (P = .01) and 4 hours (P = .0007) after sumatriptan treatment.
Study details: In a randomized, double-blind, crossover design, 30 participants received 200 mg cilostazol orally and cilostazol-induced headache was treated with subcutaneous sumatriptan.
Disclosures: The study was funded by Candys Foundation and Lundbeck Foundation. The authors declared no conflicts of interest.
Falkenberg K et al. Cephalalgia. 2020 Mar 26. doi: 10.1177/0333102420915166